Chinese Rare Disease-Focused Biotech Startup Citrine Medicine Raises US$80M Series A

Citrine Medicine aims to develop an ecosystem for rare disease patients in China

Citrine Medicine, a Chinese rare disease-focused therapeutics startup founded by Eight Roads, F-Prime Capital, and Vivo Capital, has raised $80 million in a Series A funding round, according to a press release on Monday.

The latest financing round was led by Quan Capital, a medical and healthcare-focused venture capital firm, while new investors 3H Health Investment and WU Capital also participated in the round along with the three founding backers.

The startup, which imports rare disease medicines to China, aims to deliver these drugs to the Chinese market and develop the first ever rare disease ecosystem in the country, with the prospect of helping tens of millions of patients, according to the press release.

With 20 million people suffering from rare diseases in Mainland China, and none eligible for free treatment, the market holds untapped potential for Citrine as the current treatment options are unaffordable for the majority of patients in need. Moreover, these diseases are often difficult to diagnose, difficult to treat, and difficult to guarantee recovery, according to the press report.

Since its inception in 2019, Citrine has assembled a best-in-class team of veterans with decades of work experience in rare diseases and the healthcare market in China, according to the press report.

Rebecca Lin, Partner of Eight Roads and a director of Citrine’s Board, said, “Citrine is dedicated to bringing in safe and effective medications to patients in China suffering from rare diseases. Our aspiration is to build an ecosystem of support for the patients, working together with various stakeholders to fundamentally remove the accessibility and affordability obstacles.”

Recent reforms in regulation and policy in China have expedited the drug approval process for rare disease drugs. These new regulations allow rare-disease drugs, also called orphan drugs, to be submitted for approval in China with only overseas clinical trial data.

According to the statement, Citrine will focus on validated or approved medications, while at the same time helping products speed up their development processes globally.

“Citrine is a unique platform which can leverage the resources of all investors and benefits from the synergy of this extensive network, including Eight Roads’ global resources and connections. We believe Citrine is well-positioned to build something meaningful for the rare disease community,” Lin added.

F-Prime’s Principal, Dr. Chong Xu said, “F-Prime Capital is a strong believer and long-time investor in companies developing drugs for orphan disease patients in need. We helped found Citrine because we were excited about the potential for the company to significantly improve the lives of patients and families in China affected by rare diseases.”

Dr. Wu Hui, Managing Director of Quan Capital, said, “We look forward to providing strong support for Citrine’s capabilities and pipelines in terms of talent recruitment, local operating resources, and overseas product cooperation. With the strong support of investors, we are confident that Citrine will become a leader in this field and accelerate the development of innovative rare disease drugs in China and globally.”

Header image by Volodymyr Hryshchenko on Unsplash

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email
Monika Ghosh
Monika Ghosh is a Staff Writer at Jumpstart

RELATED POSTS

Top 5 Electric Car Companies of 2022

Top 5 Electric Car Companies of 2022

Business and political conversations in recent years have shown that you simply cannot talk about progress without mentioning sustainability. Startups and big corporations are having to upgrade their business models to factor in climate change and the environment. Shoppers have taken notice, too.

Asian Startups Set to Join the IPO Race in 2022

Asian Startups Set to Join the IPO Race in 2022

Despite the pandemic, 2021 had been a bumper year for initial public offerings (IPOs). According to the 2021 EY (Ernst & Young) Global IPO Trends Report, the global IPO market had a total of 2,388 IPO deals, raising US$453.3 billion in proceeds. Global IPO activity was up 64 percent in deal numbers and 67 percent in proceeds when compared to 2020.

How-To Tech Safe Internet Navigation Tips for Seniors

How-To Tech: Safe Internet Navigation Tips for Seniors

As you get older, it gets harder and harder to keep up with the advances in technology. Also, cybercriminals are exploiting the pandemic-induced shift to the digital realm to their benefit. The elderly lose US$30 billion a year to online scams, and as of 2020, there has been a 69% increase in online scam reports.

Why Are Jack Dorsey and Elon Musk against Web 3.0

Why Are Jack Dorsey and Elon Musk against Web 3.0?

“Sounds like BS” was Tesla CEO Elon Musk’s very eloquent review of Web 3.0. After all, few people know more about BS than Musk.
Web 3.0 has been touted as the internet of the future and a new generation of webs. It aspires to decentralize the internet using blockchain-based tokens. It will allow people to “own” their internet activities, thus doing away with the power of big techs, such as Amazon, Alphabet and the like.

Virtual Concerts—The Post-COVID Future of the Music Industry

Virtual Concerts—The Post-COVID Future of the Music Industry

Much like most other industries, the music industry also saw a hefty blow from the pandemic. Be it BTS, the Weeknd, Harry Styles or Bon Jovi, a lot of major artists have had to cancel their concerts throughout 2020. To make up for these canceled live interactions with fans, artists shifted to the Internet.

Ethics of Surveying Your Remote Employees

Ethics of Surveying Your Remote Employees

For employees and employers alike, the work-from-home scenario has not been easy. Sure, we have all found ways of staying productive and getting our jobs done. Yet, for employers supervising remote employees for the very first time, remote surveillance has become the only option.